CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:
NDA 19-898/S024

Trade Name: Pravachol Tablets

Generic Name: pravastatin sodium

Sponsor: Bristol Myers-Squibb

Approval Date: January 28, 1999

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 19-898/S024

CONTENTS

Reviews / Information Included in this NDA Review.	
Approval Letter	X
Approvable Letter	
Labeling	
Medical Review(s)	
Chemistry Review(s)	X
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/ Biopharmaceutics Review(s)	
Administrative/Correspondence Document(s)	X

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 19-898/S024

APPROVAL LETTER

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

JAN 28 1999

NDA 19-898/S-024

Bristol-Myers Squibb
Attention: William J. Regan
Director, CMC Regulatory Affairs
P.O. Box 4000
Princeton, NJ 08543-4000

Dear Mr. Regan:

Please refer to your supplemental new drug application dated October 8, 1998, received October 14, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Pravachol (pravastatin sodium) Tablets.

This supplemental new drug application provides for the use of bulk drug made at [redacted] newly-expanded [redacted] facility for the manufacture of all drug product strengths at Bristol-Myers' facilities in Humacao and Mayaguez, P.R.

We have completed the review of this supplemental application and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Margaret Simoneau, R.Ph., Regulatory Management Officer, at (301) 827-6418.

Sincerely,

Stephen K. Moore, Ph.D.
Chemistry Team Leader I for
Division of Metabolism and
Endocrine Drug Products, (HFD-510)
DNDCII, Office of New Drug Chemistry
Center for Drug Evaluation and Research

`cc:
Archival NDA 19-898
HFD-510/Div. Files
HFD-510/M. Simoneau
HFD-95/DDMS (with labeling)
HFD-820/DNDC Division Director/W.Berlin/S.Moore
DISTRICT OFFICE

Drafted by: Mas/January 28, 1999
Initialed by:W.Berlin 1.28.99/E.Galliers1.28.99
final:Mas1.28.99
filename: 19898.24

APPROVAL (AP)

FOI: Please redact [redacted] and [redacted] from the above.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 19-898/S024

CHEMISTRY REVIEW(S)

JAN 25 1999

ORIGINAL

CHEMISTS REVIEW	1. ORGANIZATION	2. NDA NUMBER
	DMEDP II, HFD-510	19-898
3. NAME AND ADDRESS OF APPLICANT		4. SUPPLEMENT NUMBER, DATE
Bristol-Myers Squibb PO Box 4000 Princeton NJ 08543-4000		SCM-024 8-OCT-1998
5. PROPRIETARY NAME	6. NAME OF THE DRUG	7. AMENDMENTS, REPORT, DATE
Pravachol Tablets	Pravastatin Sodium	

8. SUPPLEMENT PROVIDES FOR

The use of bulk drug made at [redacted] newly expanded [redacted] facility, as described under [redacted] for the manufacture of all drug product strengths at Bristol-Myers' facilities in Humacao and Mayaguez PR.

9. PHARMACOLOGICAL CATEGORY	10. HOW DISPENSED	11. RELATED IND, NDA, DMF
antihypercholestremic	RX	[redacted] which describes bulk drug manufacture
12. DOSAGE FORM	13. POTENCY	
Tablets, Oral	10, 20, 40 mg	

14. CHEMICAL NAME AND STRUCTURE

See Chemistry Review #1

15. COMMENTS

The sponsor whishes to utilize bulk drug [redacted] at a [redacted] in a new facility operated by [redacted] which is described under [redacted] The scaled-up manufacture of the bulk drug was adequately described in the amendment to [redacted] dated 7 October, 1998 (see chemistry review #4 of [redacted] dated 9 December, 1998). Bristol-Myers will utilize the proposed drug substance at both their approved drug product manufacturing facilities for Pravachol, Humacao and Mayaguez PR, and for all three strengths. Additionally, the sponsor will place the first [redacted] drug product batches of tablets manufactured with material from [redacted] expanded [redacted] facility into their existing Pravachol stability program and report the results in the annual reports.

16. CONCLUSION AND RECOMMENDATION

The manufacture of the bulk drug in the [redacted] facility was described in the 7 October, 1998 amendment to [redacted] and found to be adequate (see Review #4 dated 9-DEC-1998). The proposed manufacturing facility was inspected and recommended as "Acceptable" (see attached CDER establishment evaluation report dated 21-JAN-1999). The sponsor has provided an appropriate commitment for drug product stability testing to support the use of material from [redacted] facility. Issue an approval letter.

17. NAME	18. REVIEWERS SIGNATURE	19. DATE COMPLETED
WILLIAM K. BERLIN		9-DEC-1998

DISTRIBUTION: ORIGINAL JACKET CSO REVIEWER DIVISION FILE

AP

Stephen K. Moore
1/25/99

4 Page(s) Withheld

X § 552(b)(4) Trade Secret / Confidential

_____ § 552(b)(4) Draft Labeling

_____ § 552(b)(5) Deliberative Process

Withheld Track Number: Chemistry- 19-898
5024

FDA CDER EES
ESTABLISHMENT EVALUATION REQUEST
SUMMARY REPORT

Application: **NDA 19898/024**
Stamp: **14-OCT-1998** Regulatory Due: **14-FEB-1999**
Applicant: **BRISTOL MYERS SQUIBB**
RT 206 PROVINCE LINE RD
PRINCETON, NJ 085434000

Priority: **1S** Org Code: **510**
Action Goal: District Goal: **10-JAN-1999**
Brand Name: **PRAVACHOL TABLETS**
Established Name:
Generic Name: **PRAVASTATIN SODIUM**
Dosage Form: **TAB (TABLET)**
Strength: **10, 20, 40 MG**

FDA Contacts:			
M. SIMONEAU	**(HFD-510)**	**301-827-6418**	**, Project Manager**
W. BERLIN	**(HFD-510)**	**301-827-6370**	**, Review Chemist**
S. MOORE	**(HFD-510)**	**301-827-6430**	**, Team Leader**

Overall Recommendation:

ACCEPTABLE on 21-JAN-1999 by K. COOK (HFD-324) 301-827-0062

Establishment



DMF No:
AADA No:

Profile: **CFN** OAI Status: **NONE**
Last Milestone: **OC RECOMMENDATION**
Milestone Date **21-JAN-1999**
Decision: **ACCEPTABLE**
Reason: **DISTRICT RECOMMENDATION**

Responsibilities:



CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 19-898/S024

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 19-898/S-024

OCT 21 1998

Bristol Myers Squibb
P.O. Box 4000
Princeton, NJ 08543-4000

Attention: William J. Regan
Director

Dear Mr. Regan:

We acknowledge receipt of your supplemental application for the following:

Name of Drug:	Pravachol ® (pravastatin sodium) Tablets
NDA Number:	19-898
Supplement Number:	S-024
Date of Supplement:	October 08, 1998
Date of Receipt:	October 14, 1998

Unless we find the application not acceptable for filing, this application will be filed under Section 505(b)(1) of the Act on December 13, 1998, in accordance with 21 CFR 314.101(a).

All communications concerning this NDA should be addressed as follows:

Center for Drug Evaluation and Research
Division of Metabolic and Endocrine Drug Products, HFD-510
Office of Drug Evaluation II
Attention: Document Control Room 14B-19
5600 Fishers Lane
Rockville, MD 20857

Sincerely,

Enid Galliers
Chief, Project Management Staff
Division of Metabolic and Endocrine
Drug Products, HFD-510
Office of Drug Evaluation II
Center for Drug Evaluation and Research

cc:
Original NDA 19-898/S-024
HFD-510/Div. Files
HFD-510/CSO/M. Simoneau

filename: C:\DATA\WPFILES\19898ACK.

SUPPLEMENT ACKNOWLEDGEMENT

ORIGINAL

Bristol-Myers Squibb
Pharmaceutical Research Institute

P.O. Box 5400 Princeton, NJ 08543-5400
609 818-4732 Fax: 609 818-5832

NDA NO. 19898 REF. NO. 024
NDA SUPPL FOR SCM

William J. Regan
Director, CMC
North American Regulatory Affairs

Fax 609-818-5832

Supplement to NDA 19-898
PRAVACHOL® (pravastatin sodium) Tablets

October 8, 1998

Solomon Sobel, M.D., Director
Division of Metabolism and Endocrine Drug Products (HFD-110)
Center for Drug Evaluation and Research
Food and Drug Administration
Department of Health and Human Services
5600 Fishers Lane
Rockville, MD 20857

Attention: Document Control Room (14B-03)

- Expedited Review Requested -

Dear Dr. Sobel :

Reference is made to our approved New Drug Application, NDA 19-898 for PRAVACHOL® (pravastatin sodium) Tablets; and specifically to the manufacture and control of pravastatin sodium by our approved [redacted] as described in [redacted] Additionally, reference is made to the April 30, 1998 meeting with FDA to discuss changes being made at [redacted] factory to increase pravastatin sodium production capacity.

We are submitting this supplement to NDA 19-898 to obtain FDA's approval for use of pravastatin sodium made in [redacted] expanded facility. We request an expedited review of this application, since recent approvals of various efficacy supplements are expected to increase consumer demand for PRAVACHOL® Tablets, and production of pravastatin sodium in [redacted] expanded facility is critical to assuring supply.

Bristol-Myers Squibb Company certifies that a field copy of this supplemental application has been provided to the North Brunswick office (120 North Center Drive, North Brunswick, NJ 08902) of the Food and Drug Administration. We further certify that the field copy is a true copy of this supplemental application.

A Table of Contents for this submission follows this letter.

Should you have any questions concerning this supplement, please contact me at (609)-818-4732.

Sincerely,

William J. Regan
Director
CMC for Marketed Products
Worldwide Regulatory Affairs

WJR/ccv

REVIEWS COMPLETED
CSO ACTION:
☐ LETTER ☐ N.A.I. ☐ MEMO
DATE
CSO INITIALS